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Abstract The 80kDa Myristolated Alanine-Rich C-Kinase Sub- 
strate (MARCKS) is a major in vivo substrate of protein kinase 
C (PKC). Here we report that MARCKS is a major substrate 
for the lipid-activated PKC-related kinase (PRKI) in cell ex- 
tracts. Furthermore, PRK1 is shown to phosphorylate MARCKS 
on the same sites as PKC in vitro. Thus, control of MARCKS 
phosphorylation on these previously identified 'PKC' sites may 
be regulated under certain circumstances by PRK as well as PKC 
mediated signalling pathways. The implications for MARCKS as 
a marker of PKC activation and as a point of signal convergence 
are discussed. 
Key words." Protein kinase C; PKC; PRK; MARCKS; 
Phosphorylation 
both the calmodulin and actin binding properties of MARCKS 
as well as loss of membrane binding. In addition to phosphoryl- 
ation by PKC isotypes, MARCKS has been reported recently 
to be phosphorylated in vivo by proline-directed protein ki- 
nases [12], the effect of these phosphorylations on MARCKS 
function has not yet been elucidated. 
In order to determine the potential role of PRKs in signal 
transduction pathways we have investigated cellular PRK 
substrates. In this paper we show that purified PRK1 is able 
to phosphorylate MARCKS. Moreover the resulting 
phosphopeptides are identical to those produced when 
MARCKS is subjected to phosphorylation by PKC. The results 
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1. Introduction 
The cellular substrates for the recently identified PRK ~KC-  
related kinase) family [1-3] are not yet well characterised. The 
PRK family members are closely related to the PKC super- 
family isotypes in the catalytic domain whilst retaining a dis- 
tinct amino terminal regulatory domain. Unlike the PKCs 
which characteristically retain a cysteine-rich C1 domain re- 
sponsible for effector binding, the PRKs do not encode a C1 
domain but possess two distinct conserved regulatory domains 
termed HR1 and HR2 [3,4]. Consistent with the lack of a C1 
domain it has become clear that while the PRKs resemble 
PKCs in being activated by proteolysis [5,6], they are not acti- 
vated by phorbol esters. Various fatty acids and phospholipids 
have now been shown to activate PRKs in vitro [6-9] although 
the signalling pathways leading to the activation of PRK1 in 
vivo remain unclear. 
The Myristoylated Alanine-Rich C-Kinase Substrate 
(MARCKS), has been studied extensively and characterised as 
a PKC-specific substrate (for reviews see [10,11]). The 
MARCKS protein comprises three domains: (i) an amino-ter- 
minal domain which is modified by myristoylation and is re- 
sponsible for the membrane binding properties of MARCKS, 
(ii) an MH2 domain, conserved within MARCKS family mem- 
bers, with unknown function and (iii) a basic effector domain. 
This effector domain contains the calmodulin and actin binding 
sites of the MARCKS protein in addition to the PKC phospho- 
rylation sites. PKC phosphorylation f MARCKS on serine 
residues within the effector domain results in the disruption of 
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Fig. 1. PRK1 phosphorylates an 80 kDa cellular protein. Swiss3T3 cell 
lysates were treated as follows: Lysate A: Incubated at 65°C for 10 min; 
Lysate B: Incubation at 65°C for 10 min followed by 95°C for 
5 min, incubation at 4°C for 5 min and finally centrifugation at 15,000g 
for 5 min. Lysates were then incubated for 10 min at 30°C with the 
following: Lane 1: no enzyme control; Lane 2: PRK1; Lane 3:PRK1 
and Lane 4: PKC-fll. Reactions were stopped by the addition of 10/~1 
4 × SDS sample buffer. Results were then analysed by running the 
samples on 8% SDS-PAGE and autoradiography at -80°C overnight. 
The phosphorylated 80kDa cellular protein and autophosphorylated 
PRK1 are indicated by arrows. 
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provide evidence that the MARCKS protein may act as a point 
of convergence for different signalling pathways. 
2. Materials and methods 
2.1. Materials" 
Trypsin was from Worthington. Protamine sulphate, glutathione- 
agarose and glutathione were from Sigma. [y-32p]ATP was from Amer- 
sham, cellulose thin layer chromatography plates were from Kodak. 
Foetal calf serum was obtained from Gibco Bethesda Research Labora- 
tories. 
2.2. Tissue culture 
Swiss3T3 fibroblasts were seeded and made quiescent as described 
previously [13]. 
2.3. Protein purification 
In order to obtain recombinant MARCKS protein, GST-MARCKS 
fusion protein was purified from Escheriehia coli cells (XL-1 Blue, 
Stratagene) by glutathione affinity chromatography as described previ- 
ously [14]. Recombinant PRK1 was purified from COS 7 cells as de- 
scribed [6]. Recombinant PKC-fll was expressed and isolated from 
baculovirus-infected insect cells [15]. 
2.4. Two-dimensional peptide mapping 
Phosphorylated GSToMARCKS protein was digested overnight at 
room temperature with 20/tg/ml trypsin (Sigma). The resulting tryptic 
phosphopeptides were dried under vacuum and resuspended in 20/~1 
ofelectrophoresis buffer (pH 3.5; pyridine/acetic a id/water (1 : 10: 189). 
The samples containing 0.1 1.0 x 106 cpm were spotted on TLC plates 
and subjected to electrophoresis at 50 mA for 20 min. After drying, the 
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Fig. 2. PRK1 phosphorylates MARCKS in vitro. The kinetics of 
MARCKS phosphorylation byintact PRK1 and trypsinised PRK1 are 
compared. (Panel A) PRK1 activity towards MARCKS peptide for 
intact PRK1 (o-o) and PRK1 trypsinised with 8/.tg/ml trypsin (o-e) 
are shown. (Panel B) PRK1 activity towards GST-MARCKS fusion 
protein for intact PRK1 (o-o) and PRK1 trypsinised with 8 /zg/ml 
trypsin (~o)  are shown. Assays were carried out in duplicate at 30°C 
for 10 min and stopped by spotting onto Whatman P81 paper and 
placing in 10% acetic acid. The filters were washed 3 x 10 min in 30% 
acetic acid, and incorporation determined by Cerenkov radiation. 
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Fig. 3. Relative activities of PRKI and PKC-fll for MARCKS. Equal 
units of both PRK1 and PKC-fll were activated, by limited proteolysis 
or with phosphatidylserine/TPA respectively, and a time-course of 
GST-MARCKS phosphorylation carried out. Reactions were stopped 
by the addition of 4 x SDS sample buffer and subsequent boiling for 
5 min, samples were then analysed by 8% SDS-PAGE followed by 
autoradiography at -80°C. 
TLC plate was chromatographed in the second dimension in chroma- 
tography buffer (n-butanol/pyridine/acetic ac d/H20 (75 : 50 : 15 : 60)). 
The plate was then dried and phosphorylated peptides detected by 
autoradiography at -80 ° C. 
2.5. Preparation of COS 7 cell lysates jor phosphorylation 
Cell lysates were prepared by lysis of COS 7 cells (two plates of 
1 X 10  6 cells) into 500/11 lysis buffer (60 mM Tris-HC1 pH 7.5, 100 mM 
NaCI, 5 mM EDTA, 0.3% (v/v)fl-mercaptoethanol, 100/IM Na3VO4, 
50 mM NaF, 1% (v/v) Triton X-100, 50 gt/ml phenylmethylsulfonyl 
fluoride (PMSF), 10 mM benzamidine, 125/lg/ml aprotinin, 250 ,ug/ml 
leupeptin). The extracts were then treated for I0 min at 65°C to inacti- 
vate endogenous protein kinases. After this, lysate A (50%) was stored 
at 40°C. Lysate B was further treated with a 5-rain incubation at 95°C 
followed by centrifugation for 10 rain at 15,000 x g to remove heat 
insoluble proteins. 
2.6. Other procedures 
SDS-PAGE was according to Laemmli [16]. Protein was determined 
by the method of Bradford [17] using bovine serum albumin as a 
standard. 
3. Results and discussion 
3.1. PRK I  phosphorylates an 80 kDa protein from COS 7 cell 
lysates 
To assess the substrate specificity of PRK 1, crude COS 7 cell 
lysates (25 ill) were incubated with 5 H1 PRK1 or PKC-fl (equiv- 
alent to 2.5 Units), 5 H1 10 mM MgC12 and reactions tarted by 
the addit ion of [y-32p]ATP. Reactions were then incubated for 
10 min at 30°C, and stopped by the addit ion of 10 HI 4 x SDS 
sample buffer. The phosphorylated proteins were seperated on 
8% SDS-PAGE and detected by autoradiography at -80°C 
____) 
Fig. 4. Two-dimensional nalysis of MARCKS phosphopeptides. Re- 
combinant GST-MARCKS was maximally phosphorylated (4 hours) 
by PRK1 (Panel A) and PKC-fll (Panel B) resolved by PAGE and the 
protein digested with trypsin at 37°C overnight. Tryptic phnsphopep- 
tides were resolved in the first dimension by electrophoresis at pH3.5 
and by thin-layer chromatography in the second imension. The arrow 
marks the origin. Equal cpms of PRK1 and PKC-fll-derived tryptic 
phosphopeptides were mixed and analysed as before (Panel C). TLC 
plates were dried and analysed by autoradiography at -80°C. Panel D 
indicates the results of phosphopeptide sequencing of the major tryptic 
phospopeptides: Peptide 1: LSGFS*FK, Peptide 2: LSGFS*FKK, Pep- 
tide 3: RFS*FKK, Peptide 4: S*FK and Peptide 5: KS*FK. * denotes 
modification of the serine residue by phosphorylation as identified by 
sequencing (from reference [19]). 
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overnight (Fig. 1). PRK1 was found to phosphorylate s veral 
cellular proteins including the prominent phosphorylation of
an 80 kDa protein. The following observations pointed to the 
identification of this protein as MARCKS: (i) the PRK1 
substrate was of equal apparent molecular mass (80 kDa) as 
previously described PKC substrate MARCKS, (ii) the 
C substrate was a heat stable protein - a characteristic of 
MARCKS (Fig. 1; lane 3), and (iii) the 80 kDa PRK1 substrate 
co-migrated in SDS-PAGE together with the prominent band 
of 80 kDa phosphorylated by PKC-fl (Fig. 1; lane 4). 
3.2. PRK1 can phosphorylate MARCKS in vitro 
In order to determine whether MARCKS is a substrate for 
PRK1, purified MARCKS (see section 2) and a MARCKS 
peptide corresponding to 145-KKKKKRFSFKKSFKLSGF- 
SFKKSKK -169 (according to the murine sequence; [18]) were 
employed. 
Phosphorylation of MARCKS was carried out using intact 
PRK 1 or PRK 1 which was fully activated by limited proteolysis 
[6]. PRK1 was tested for its ability to phosphorylate MARCKS 
peptide (Fig. 2; Panel A) and GST-MARCKS (Fig. 2; Panel B). 
Full length PRK1 was able to phosphorylate GST-MARCKS 
although inefficiently when compared to PRK 1 which had been 
activated by proteolysis. Importantly, PRK1 was not able to 
phosphorylate he GST moiety alone (data not shown). Prote- 
olysis of PRK1 resulted in a >10-fold increase in phosphoryla- 
tion of GST-MARCKS with a dramatic increase in Vmax. In 
contrast he proteolytic activation of PRK1 resulted in only a 
2-fold increase in activity towards the MARCKS effector do- 
main peptide (Fig. 2A). This peptide, which contains the three 
in vivo PKC serine phosphorylation sites, was efficiently 
phosphorylated bythe full length PRK1 enzyme. This probably 
reflects the ability of the MARCKS peptide to diffuse more 
easily into the active site of the kinase, therefore overcoming 
to some extent he inhibitory regulation imposed on the kinase 
domain of PRK1 by its amino-terminal regulatory domain. 
This clearly constrasts with intact MARCKS which is a poor 
substrate for the PRK1 holoenzyme. The PRKI (intact or fol- 
lowing partial proteolysis) Km for the MARCKS peptide is - 1 
pM which compares with values of between 0.4 and 10 pM for 
different PKC isotypes determined in this laboratory [19]. 
3.3. PRK1 and PKC-f l l  phosphorylate MARCKS on the same 
sites 
The ability of PRK1 to phosphorylate MARCKS was com- 
pared with that of PKC-fll. Equal units of PRKI and PKC-fll 
activity were titrated using the substrate protamine sulphate 
which is phosphorylated in an effector independent manner by 
both of these kinases (data not shown). Equivalent units of both 
PRK1 and PKC-fll were activated by limited proteolysis or 
with phosphatidylserine/TPA respectively, and a time course of 
GST-MARCKS phosphorylation activity carried out (Fig. 3). 
Both PRK1 and PKC-fl phosphorylated GST- MARCKS to a 
similar extent and the reaction was essentially complete by 90 
min. This data demonstrates that both PRK1 and PKC-fll are 
equipotent in their ability to phosphorylate the full length 
MARCKS protein. 
In order to further study the phosphorylation f MARCKS 
by PRK1, GST-MARCKS was incubated with both activated 
PRK1 and PKC-fll to achieve full phosphorylation of 
MARCKS. Phosphorylated GST-MARCKS was then purified 
by 8% SDS-PAGE and the corresponding gel band digested 
overnight with 2 pg of trypsin. The resulting samples were then 
subjected to 2-dimensional e ectrophoresis a described in the 
materials and methods (Fig. 4; Panels A and B). Examination 
of the tryptic phosphopeptides of GST-MARCKS for both 
PRK1 and PKC-fll revealed a similar pattern in each case. In 
order to confirm that these phosphopeptides were identical, 
equal cpm of (i) PRK1 and (ii) PKC-fll-phosphorylated 
MARCKS tryptic peptides were mixed and once again anal- 
ysed by 2-dimensional electrophoresis (Fig. 4; Panel C). The 
phosphopeptides derived from PRK1 and PKC-fll phos- 
phorylated MARCKS did indeed co-migrate and were there- 
fore judged to be identical. The major tryptic phosphopeptides 
have been analysed previously [19] and identified as: Peptide 1: 
LSGFS*FK, with one phosphate; Peptide 2: LSGFS*FKK, 
with one phosphate this peptide is identical to Peptide 1 apart 
from the inclusion of an extra lysine residue; Peptide 3: 
RFS*FKK, with one phosphate; Peptide 4: S*FK, with one 
phosphate and Peptide 5: KS*FK, with one phosphate (Fig. 
4D) [19]. 
Confirmation of the phosphorylation sites was obtained by 
direct sequence analysis. The MARCKS peptide was 
phosphorylated to completion (3.0 mol phosphate/mol peptide) 
by proteolytically-activated PRK1 and purified on a C18 car- 
tridge. Sequential Edman degradation yielded [32p]phosphate 
release at cycles 8, 12 and 19 (data not shown). This identifies 
the phosphorylated serine residues as 152, 156, and 163. The 
serines at 160 and 167 were not phosphorylated as observed for 
PKC (see [19]). 
3.4. Conclusions 
The data shown here clearly demonstrate he ability of PRK 1 
to phosphorylate the MARCKS protein in vitro. Indeed in 
Swiss 3T3 cell extracts this protein is a major substrate for 
PRK1. The sites phosphorylated by PRK1 are identical to 
those previously characterised as PKC phosphorylation sites 
within the MARCKS effector domain. Thus the phosphoryla- 
tion of MARCKS at these sites may not provide unequivocal 
evidence for the action of PKC. 
The identical site specificity demonstrates that PRK, like 
PKC, has the capacity to regulate the ability of MARCKS to 
bind calcium/calmodulin [20] and crosslink actin [21], both of 
which are disrupted by phosphorylation at these sites. That 
PRK 1 is able to phosphorylate MARCKS is consistent with the 
domain structure of this family of kinases, which comprises a
carboxy-terminal kinase domain that is most highly related to 
the PKC family [3]. The implication of these results is that the 
control of MARCKS effector function may be regulated by 
different signalling pathway inputs, i.e. via both a lipid-acti- 
vated PRK pathway in addition to the well characterised and 
established phorbol ester/diacylglycerol-activated PKC-medi- 
ated pathways. That MARCKS may be a physiological target 
for PRK is consistent with the finding that in crude lysate 
preparations it appears to be the major substrate. A dissection 
of the role of PRK family kinases in the regulation of 
MARCKS in vivo awaits identification of a specific activator 
for these kinases. 
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